Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 HAS Group, Biodelphis Therapeutics Partner to Advance Antibody Protease Inhibitor Conjugates | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

HAS Group, Biodelphis Therapeutics Partner to Advance Antibody Protease Inhibitor Conjugates

The collaboration combines HAS Group’s expertise in complex bioconjugation, process development, and clinical-grade manufacturing with Biodelphis Therapeutics’ APIC platform.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics have signed a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease-driving proteases.

This collaboration combines HAS Group’s expertise in complex bioconjugation, process development, and clinical-grade manufacturing with Biodelphis Therapeutics’ APIC platform, a novel drug modality engineered to deliver highly selective protease inhibition directly to diseased tissues.

Under the agreement, the two companies will work closely to accelerate the transition of first-in-class APIC candidates from early development into robust, scalable manufacturing processes. The partnership aims to strengthen the path toward clinical evaluation by integrating Biodelphis’ therapeutic design with HAS/Cerbios’ capabilities in high-quality bioconjugate production.

The partnership marks a shared commitment to advancing next-generation targeted therapies for patients with high unmet medical needs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics